Two cycles of continuous intravenous chemotherapy, 28 days apart, were administered before surgery. For the experimental group, the treatment regimen consisted of 120 mg/m2 d1 oxaliplatin (L-OHP) with 175 mg/m2 d1-3 dacarbazine (DTIC). The control group received standard VAC chemotherapy 1 mg/m2/d1 vincristine (VCR), 60 mg/m2 d1 epirubicin (Epi-ADM), and 600 mg/m2 d1 cyclophosphamide A-1155463 solubility dmso (CTX). Surgical procedures consisting of extensive resection or muscle excision were

Akt inhibitor carried out four weeks after the second cycle, followed by another 2-4 cycles of chemotherapy using the same pre-surgical treatment. Post-operative radiotherapy was undertaken by 3 cases in the experimental group and 10 cases in the control group, respectively. Endpoints and adverse reactions The primary endpoint was progression-free survival, while Brigatinib solubility dmso the secondary endpoints were toxicity of chemotherapy and efficacy of chemotherapy determined by CT or MRI before prior to surgery. Chemotherapeutic response was evaluated using the RECIST

criteria. Complete response (CR) was defined as the disappearance of tumors (on the basis of CT scan results) for over 4 weeks, partial response (PR) was defined as the reduction of overall tumor volume by more than 50% for over 4 weeks, and stable disease (SD) was defined as a less than 25% reduction in tumor volume. Chemotherapy toxicity was evaluated in accordance with the CTCAE v3.0 issued by MTMR9 the NCI on August 9, 2006. Statistical Analyses Chemotherapeutic response, surgical margins and therapeutic

outcomes were compared between experimental and control groups using Chi-square analyses. Progression free survival time of each group was compared by Log-Rank test. The correlations between chemotherapeutic regimen, chemotherapeutic response, surgical margin and therapeutic outcomes were tested using Pearson’s multivariate correlation analyses. All statistical analyses were performed using the SPSS11.5 Software Package. Results The results from the response evaluation after two cycles of chemotherapy were as follows: 2 CR, 11 PR, and 2 SD in the experimental group; 1 CR, 5 PR, 10 SD in the control group. The difference of response between the two groups was found to be statistically significant (χ2 = 7.878, p < 0.05; Table 2). The tumor response rate in the experimental group was 87%, while the tumor response rate in the control group was 38%, correspondingly. Limb-preserving operations were carried out in each case of both groups. But there were 2 cases got positive surgical margin in the experimental group, while 10 cases got positive surgical margin in the control group. Both chemotherapy regimens were well-tolerated with no significant difference between experimental and control group (χ2 = 0, p > 0.05). In both groups, no treatment-related deaths occurred, and all adverse reactions were below grade II.